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Peak r c c  incidence occurs in patients more than 
65 years of age 4. Patients in that age group often have 
significant medical comorbidities that might affect the 
choice of therapeutic options.
Management of s r m s must be individualized, 
because several patient- and tumour-related factors 
affect management strategy. The identification of 
these parameters necessitates revisiting the natural 
history of s r ms and the safety and efficacy of the 
various available treatment modalities.
2.  NATURAL HISTORY OF SRMs
Understanding the biologic behaviour and natural 
history of s r m s is crucial in predicting tumour growth 
and metastatic potential, so as to properly select the 
methods and optimal timing of intervention.
2.1  Pathologic Features
A significant number of s r m s will prove to be benign. 
Vasudevan et al. reported a 33% benign histology 
in 70 renal masses smaller than 5 cm 5. Similarly, a 
report of 100 laparoscopic partial nephrectomies for 
a mean tumour size of 2.9 cm showed that 32% of 
the surgeries were performed for benign disease, as 
indicated by the final pathology specimen 6.
The common perception that s r m s are always in-
dolent tumours is not completely true. Of renal masses 
smaller than 4 cm, 20%–30% are reported to be ag-
gressive tumours with highly metastatic potential, 
even if dimensionally small 7,8. Other reported series 
identified aggressive pathology features in 25%–38% 
of s r m s 7,9. In addition, Hsu et al. also demonstrated 
extracapsular extension in 38% of 50 resected r c c s 
smaller than 3 cm 7.
Lesions between 3 cm and 4 cm in diameter are 
most likely to have aggressive pathologic features. 
Perinephric fat invasion is found in 4.2% of tumours 
smaller than 2 cm, 14.9% of tumours 2.1–3 cm, and 
35.7% of tumours 3.1–4 cm 9. The Fuhrman grade of 
small r c c  tumours is low in most cases; only 5%–6.5% 
of tumours 2–3 cm and 18.7%–25.5% of tumours 
3–4 cm have a high Fuhrman grade (3 or 4) 9,10.
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has led to a significant change in the approach to 
renal masses. New options such as observation or 
energy ablation are gaining popularity in a subset 
of this patient population. In addition, the observed 
changes directly contribute to the increased use of 
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1.  INTRODUCTION
Small renal masses (s r ms) are defined as cortical renal 
masses smaller than 4 cm in diameter. An observed 
stage migration is contributing to the increased detec-
tion of s r m s. Between 1983 and 2002, the incidence 
of renal tumours 2–4 cm in diameter more than tripled 
to 3.3 from 1.0 cases per 100,000 1. In the 1970s, 
approximately 10% of renal cell carcinomas (r c c s) 
were discovered incidentally, as compared with 60% 
in 1998 2.
Increased detection of asymptomatic s r ms can-
not be fully explained by the more frequent use of 
abdominal imaging. Mindrup et al. compared the 
frequency of detection of occult r c c  at autopsy for 
the periods 1955–1960 and 1991–2001, and noticed 
that, despite the recent use of more frequent and 
sophisticated imaging techniques, no difference 
was evident in the frequency of occult r c c  (0.4% 
and 0.5% respectively) 3. In that series, the mean 
size of the occult r c c  detected at autopsy in the 
earlier period was about one third the size of the 
tumours detected in the more recent group (1.65 cm 
vs. 4.63 cm) 3.NATURAL HISTORY AND MANAGEMENT OF SMALL RENAL MASSES
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As indicated earlier, s r m s show heterogeneous 
pathologic features ranging from totally benign to 
highly aggressive, and hence determination of the 
exact nature of an incidentally discovered mass is 
crucial before a treatment decision is made.
2.2  Progression
Although the growth rates of s r m s can vary consid-
erably, a recent meta-analysis of clinically localized 
tumours determined an overall median growth rate 
of 0.28 cm annually for lesions under active surveil-
lance at a mean follow-up of 34 months (median: 32 
months; range: 26–39 months) 4. Moreover, Kunkle 
et al. reported that 26%–33% of incidentally detected 
renal masses demonstrate zero net growth when 
observed 11.
The aggressive potential of small renal masses 
was studied. A recent review revealed an association 
with tumours 3.0 cm or smaller in up to 5% of patients 
with synchronous r c c  metastases 12. Minardi et al. 
evaluated 48 patients with pT1a clear-cell r c c  who 
underwent nephron-sparing surgery (n s s ). Of these 
48 patients, 3.9% died of metastatic renal cancer at 
a median follow-up of 2 years 13. Distant metastases 
occurred in 2.4% of patients with tumours smaller 
than 3 cm as compared with 8.4% of patients with 
tumours between 3.1 cm and 4 cm 9. This informa-
tion clearly supports the variable and occasionally 
unpredictable behaviour of s r m s.
2.3  Predictors of Progression
To properly select the appropriate treatment strategy, 
it would be helpful to establish clinical and pathologic 
predictors of future tumour growth or progression to 
metastatic disease. Initial tumour diameter, tumour 
growth rate, and age have been examined with regard 
to patient outcomes.
2.3.1   Initial Tumour Size
Tumour size at presentation was found not to correlate 
with growth rate in the meta-analysis published by 
Chawla et al., nor in our recently published series 4,14. 
However, tumour size is a significant clinical predic-
tor for the presence of biopsy-proven synchronous 
metastatic r c c . Kunkle et al. reported a 22% increased 
in the odds of synchronous metastasis with each cen-
timetre increase in tumour size 12.
2.3.2  Growth Rate
The behaviour of s r m s remains difficult to predict. 
Kunkle et al. compared radiographic and pathologic 
characteristics of enhancing renal masses under ac-
tive surveillance with zero net radiographic growth 
to those with positive growth 11. Pathology assess-
ment confirmed the same incidence of malignancy 
in tumours with either zero growth rate or with a 
positive growth rate (83% and 89% respectively, 
p = 0.56), suggesting that growth rate is not indicative 
of malignant or benign histology 11.
2.3.3  Age
In the observational study by Kouba et al. of renal 
masses, patients under 60 years of age had a trend 
toward a more rapid rate of tumour growth than did 
patients 60 years of age and older (0.90 cm vs. 0.60 cm 
annually, p = 0.0570) 15. Although the rationale for 
observation appears to be safe in selected older pa-
tients, younger patients tend to have faster-growing 
tumours, supporting treatment at diagnosis because 
of the potential for progression.
3.  DIAGNOSIS OF SRMs
Accurate differentiation of s r m s between categories 
of benign and malignant histology is the cornerstone 
of the treatment decision.
3.1  Imaging and Pathology
Benign lesions such as simple cysts and angiomyoli-
pomas usually have classic imaging features allowing 
for an accurate diagnosis. However, oncocytomas and 
occasionally low-fat angiomyolipomas are often difficult 
to differentiate from r c c s with current imaging mo-
dalities. Remzi et al. found that only 17% of all benign 
lesions were correctly identified as benign on preop-
erative computed tomography (c t) imaging, and that 
43% of patients who were assessed incorrectly on pre-
operative c t  underwent unnecessary radical surgery 16.
3.2  Initial Tumour Size
Evaluation of 1208 s r m s confirmed a prevalence 
of benign lesions of 15%, 14%, and 14% in the 
tumour size ranges of 0.1–1.0 cm, 1.1–2.0 cm, and 
2.1–3.0 cm respectively. However, the incidence of 
benign lesions decreased significantly in tumours 
measuring 3.1–4.0 cm (8%, p = 0.001) 17. Similarly, 
Frank et al. reviewed the pathology specimens of 
2770 patients and found that each 1 cm increase in 
tumour size was associated with a 17% increase in 
the odds of malignancy 10.
Two recent studies attempted to correlate pathology 
characteristics and tumour diameter 9,18. Remzi et al. 
studied 287 tumours smaller than 4 cm in diameter 
and found a significant increase in the probability of 
multifocality, higher nuclear grade, type 2 papillary 
r c c , advanced stage, and distant metastases with in-
crease in diameter 9. Pahernik et al. also observed a 
sharp increase in the incidence of adverse prognostic 
parameters in tumours greater than 3 cm 18.
3.3  Tumour Growth Rate
Tumour growth rate is not an ideal parameter for pre-
dicting tumour histology. Chawla et al. demonstrated ABOU YOUSSIF and TANGUAY
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no statistical difference in mean tumour size at diag-
nosis (2 cm vs. 2.2 cm) or mean growth rate (0.16 cm 
vs. 0.35 cm annually) between oncocytomas and r c c  
under observation 4.
3.4  Preoperative Nomogram
In an effort to help predict preoperative histology, a 
nomogram was created. After analysis of 862 s r m s, 
the probability of benign—or likely indolent—pa-
thology findings was modeled using a multivariable 
logistic regression model based on age, sex, radio-
graphic tumour size, symptoms at presentation, and 
smoking history. According to this nomogram, s r m s 
in older men and younger women are more likely to 
be benign 19.
3.5  Role of Renal Biopsy
Imaging alone being unable to reliably define the na-
ture of s r m s, histologic confirmation can be obtained 
by percutaneous biopsy. Percutaneous needle biopsy 
remains underutilized by urologists because of a 
perception of unreliability. However, contemporary 
use of renal biopsy has proved to be reliable in most 
patients.
Renal biopsy could help to select the optimal 
treatment strategy and possibly to avoid nephrectomy 
for benign lesions. In a recent study, biopsy with an 
18-gauge needle was performed for 235 masses. Of 
these masses, 184 had an appropriate diagnostic. 
The accuracy of the biopsy result was confirmed in 
108 renal surgeries, confirming a 100% biopsy ac-
curacy rate in distinguishing malignant from benign 
lesions and a 98% ability to determine the histologic 
tumour type 20. Neuzillet et al. reported on 88 biop-
sies performed in solid s r m s. Histopathologic tumour 
type was accurately identified in 92%, and Fuhrman 
nuclear grade, in 69.8% 21.
The identification of diagnostic and prognostic 
molecular markers to be evaluated in the renal biopsy 
is underway and will hopefully help to define the r c c s 
that are likely to exhibit aggressive behaviour.
4.  TREATMENT OPTIONS
A variety of treatment options for patients with s r m s 
have evolved over the years. These options range 
from surgical excision, through ablative techniques, 
to active surveillance.
4.1  Surgical Excision
Surgical excision remains the “gold standard” for the 
management of s r m s. The improved understanding of 
the effect of radical nephrectomy in promoting the 
development of chronic kidney disease reinforces the 
importance of n s s  when feasible. As compared with 
partial nephrectomy, radical nephrectomy has been 
associated with an increase in long-term mortality 
[risk ratio (r r ): 2.16; p = 0.02] 22. Moreover, partial 
nephrectomy has also been associated with a better 
health-related quality of life secondary to preservation 
of renal function and of overall quality of life 23.
Partial nephrectomy has proved to be a surgical 
approach associated with low morbidity and high 
patient satisfaction that also provides excellent on-
cologic and functional outcomes at 10 years 24. The 
acceptance of elective n s s  for tumours smaller than 
4 cm and also potentially for all tumours smaller than 
7 cm should lead to an increase in the number of n s s s 
performed 25.
In an effort to minimize morbidity, laparoscopic 
partial nephrectomy has emerged as a minimally 
invasive approach that is technically feasible in ex-
perienced hands 26. Gill et al. compared outcomes in 
1800 patients undergoing open partial nephrectomy 
by experienced surgeons with the initial experience 
with laparoscopic partial nephrectomy in patients 
with a single renal tumour smaller than 7 cm 27. Lap-
aroscopic partial nephrectomy was associated with a 
shorter operative time, reduced operative blood loss, 
and a shorter hospital stay 27. Laparoscopic partial ne-
phrectomy was, however, associated with longer warm 
ischemia time. For patients with a solitary T1N0M0 
r c c , 3-year cancer-specific survival was 99.3% and 
99.2% after laparoscopic and open partial nephrec-
tomy respectively 27. A recently published report of 
oncologic and renal functional outcomes 5 years after 
laparoscopic partial nephrectomy showed excellent 
results, comparable to those of open n s s  28.
4.2  Thermal Ablation
Minimally invasive ablative techniques using vari-
ous forms of energy to ablate renal tumours, such 
as radiofrequency ablation or cryotherapy are also 
gaining acceptance 29.
4.2.1  Cryotherapy
Cryoablation can be performed either percutaneously 
or in a laparoscopic approach; however, the percu-
taneous approach may be associated with inferior 
outcomes as compared with a standard laparoscopic 
approach 30.
During therapy, the ice ball created by the cryo-
probes can be monitored in real time by ultrasound, 
magnetic resonance imaging, or laparoscope to ensure 
that the intended area is fully treated 31. The maximum 
recommended lesion size for cryoablation of r c c  is 
4.0 cm. Potential complications of cryoablation in-
clude hypothermic damage to normal tissue adjacent 
to the tumour, injury to adjacent organs, structural 
damage along the probe track, and development of 
secondary tumours if cancer cells are seeded during 
probe removal 31.
Cryoablation has proved to be oncologically 
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patients undergoing laparoscopic renal cryoablation. 
At 3 years, cryolesions were 75% smaller, and 38% 
had completely disappeared 32. Postoperative needle 
biopsy found local recurrence in only 2 patients 32. 
Longer-term oncologic data are required to validate 
renal cryoablation as a treatment modality for patients 
with s r m s.
Recently a novel approach using s p a r c  (single-port 
access renal cryoablation) for s r m s was proposed 33. 
In this technique, the entire cryoablation procedure is 
performed laparoscopically through a single port. The 
ability to monitor the progression of the ice ball with 
laparoscopic ultrasound, the ability to directly follow 
the development of the ice ball, and the opportunity 
to properly control any post-treatment bleeding from 
the site of renal puncture can be considered the most 
attractive features of this novel approach.
4.2.2  Radiofrequency Ablation
Radiofrequency ablation (r f a ) uses alternating 
electric current to heat tissue, causing cell death 
and ischemia leading to coagulative necrosis. The 
application of radiofrequency produces resistive fric-
tion that is converted into heat in the tissue. Heating 
tissues above 50°C induces cellular destruction and 
protein denaturation 31. The primary advantage of r f a  
over cryosurgery is its easier application: r f a  is less 
cumbersome, uses smaller probes, and is a portable 
technique. However, with the currently available 
r f a  technology, real-time monitoring of the treated 
area remains difficult 32. Kunkle and colleagues 
demonstrated in a meta-analysis that, as compared 
with cryoablation, r f a  is associated with a high risk 
of local progression and a higher risk of the need for 
a repeat ablation.
4.3  Active Surveillance
The practice of active surveillance is contrary to all 
conventional treatment standards, which advocate early 
surgical removal of all suspected renal malignancies. 
Yet, available data on untreated renal tumours suggest 
that most s r ms tend to have a long natural history as-
sociated with slow growth rate and limited risk of me-
tastasis, suggesting that in selected patients, treatment 
can often safely be delayed 34. Recently, Crispen et al. 
reported on outcomes in 82 patients with 87 s r ms who 
had a median of 14 months’ delay (mean: 21 months; 
range: 6–97 months) in their management 35. Overall, 
66 of 87 tumours (76%) were surgically removed. 
Local disease recurrence was noted in the remnant 
kidney in only 1 of 73 patients (1%) with pathology-
confirmed r c c . The estimated 1-year and 3-year cancer 
recurrence–free survival rates for these patients were 
100% and 99%. No cancer-related deaths occurred, 
and no patient developed metastatic disease before or 
after intervention 35.
Many studies have evaluated outcomes in patients 
undergoing active surveillance for their s r ms 4,14,34–42. 
Indications for observation included one or a com-
bination of the presence of significant comorbidi-
ties, patient choice, potential need for postoperative 
dialysis, a tumour in a solitary kidney, or bilateral 
renal tumours 4,34–39,42. All published series demon-
strated a limited growth rate during the observation 
period and a low risk of metastasis in the absence of 
tumour growth.
We previously reported our initial experience in 
the observation of 24 patients with s r m s. After an aver-
age of 32 months of observation, tumour growth was 
demonstrated in 5 patients, and no patients developed 
metastatic disease during the observation period 36.
In a recent meta-analysis, Chawla et al. analyzed 
the published experience with 286 s r ms followed 
conservatively 4. Mean tumour size at presentation 
was 2.6 cm (median: 2.48 cm). Patients were followed 
for a mean of 34 months (median: 32 months; range: 
26–39 months). Mean and median annual growth rates 
of 0.28 cm were observed 4. Progression to metastatic 
disease was reported in only 3 patients representing 
1% of the entire patient cohort followed. The authors 
concluded that, under observation, most enhancing 
s r m s will grow at a slow rate. Initial and serial ra-
diographic evaluation remain unable to predict the 
likelihood of progression for these lesions 4.
Recently, we published our updated experience 
in active surveillance for s r m s 14. We followed 35 
patients for a mean of 44.3 months. Patients had tu-
mours with a median diameter of 2.1 cm at the time 
of diagnosis. The mean annual size-growth rate of the 
tumours was 0.21 cm, and the mean and median an-
nual volume-growth rates were 2.7 cm3 and 1.4 cm3. 
Progression to metastatic disease was observed in 2 
patients (5.7%). In 8 patients (22.9%), the tumour was 
surgically resected, and in 8 patients (22.9%), death 
occurred from other causes. Two patients (5.7%) 
were lost to follow-up 14. We concluded that, under 
observation, most renal masses will grow and may 
require treatment. Initial tumour size cannot help to 
predict the natural history of renal cancer 14.
Metastasis represents the most significant risk 
associated with surveillance in patients with r c c  be-
cause the treatment options for metastatic r c c  have 
limited success, and thus, the disease is converted 
from curable to disease beyond cure.
Overall progression to metastatic disease in re-
ported observational studies range from 0%–5.7%. 
In the meta-analysis by Chawla et al., a 1% rate of 
progression to metastatic disease in the renal lesions 
under active surveillance was noted 4. Several factors 
may contribute to this low rate of observed progres-
sion to metastatic disease: small cohort, relatively 
short duration of follow-up, and presence of benign 
disease in many of the observed patients.
In our recently published series (which has the 
longest reported follow-up to date), we also reported 
the highest rate of progression to metastatic disease 
(5.7%) 14. One patient presented with a 2.7-cm renal ABOU YOUSSIF and TANGUAY
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mass. After an initial period of observation, the patient 
was lost to follow-up and presented 40 months after 
the initial diagnosis with spinal cord compression 
attributable to metastatic disease. At the time of the 
diagnosis of metastasis, the renal mass measured 5.8 cm 
in the greatest dimension. Retrospectively, an annual 
growth rate of 0.95 cm was calculated. A second 
patient also presented with a 2.7-cm renal mass. An 
annual growth rate of 0.9 cm was observed. Given 
the constant size progression, the patient was offered 
surgical resection after 26 months of follow-up. The 
pathology evaluation demonstrated a conventional 
r c c , stage pT3aN0M0, Fuhrman grade 3. Lung me-
tastasis and malignant pleural effusion occurred 3 
months after surgery. The patient died of metastatic 
disease 6 months later 14. Thus, we can conclude that 
metastasis in s r m s can occur even after a long period 
of follow-up.
Given the risk of metastasis and the absence of 
curative treatment in patients with metastatic disease, 
we must ensure that active surveillance is offered 
only to appropriate patients with competing health 
risks. Active surveillance for s r ms is still lacking 
guidelines and cut-off values at which intervention 
should be considered.
A recent meta-analysis compared surveillance, 
n s s , cryoablation, and radiofrequency ablation for 
the treatment of small renal lesions. A total of 99 
studies were examined. The most disturbing finding 
was the significantly higher rates of local progres-
sion for cryoablation (r r : 7.45) and radiofrequency 
ablation (r r : 18.23). No difference was observed 
in the rates of metastatic progression between the 
modalities examined. The authors concluded that the 
current data support n s s , ablation, and surveillance 
as viable strategies for s r m s based on short-term and 
intermediate-term oncologic outcomes. However, 
a significant selection bias currently exists in the 
clinical application of these techniques with regard to 
patient age and tumour size. Giving the comparable 
outcomes and cancer-specific survivals seen with all 
management modalities, the authors suggested the 
existence of an overtreatment bias for s r m s.
5.  CONCLUSIONS
Small renal masses represent a heterogeneous dis-
ease ranging from benign to potentially highly ma-
lignant tumours. The natural history of solid renal 
masses is gradually being understood, and the use 
of surveillance as a treatment option is still being 
characterized.
Because no diagnostic imaging technique can 
predict the biologic behaviour of renal masses, the use 
of renal biopsy at the time of diagnosis should help 
in the selection of the best treatment alternative. The 
discovery, development, and validation of new tu-
mour markers to help predict potential tumour growth 
and disease progression remain essential steps in the 
understanding and prediction of r c c  behaviour.
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